Honeywell Split Into 3 Companies. Here's Which One I'd Buy for the Aerospace Boom.

Honeywell Aerospace is positioned as the strongest Honeywell-linked beneficiary of aerospace spending growth, supported by an $18.1B backlog and an estimated $15B in lifetime value from year-to-date contract wins. Q2 sales rose 5% year over year to $4.5B, but adjusted EPS fell 32% to $1.87 amid separation costs and long-term debt surged to $15.85B from $4M. The company cut full-year sales-growth guidance to 4%-5% from 7%-9%, contributing to an over-18% post-spinoff share-price decline, though its defense and commercial aftermarket exposure provides longer-term cash-flow visibility.

Analysis

HONA’s separation creates a cleaner aerospace multiple, but the key underwriting issue is not order visibility—it is conversion of backlog into free cash flow after standalone costs, working-capital needs, and a materially more levered capital structure. The equity can rerate over 6-18 months if aftermarket mix and supply-chain normalization lift conversion, but near-term earnings remain exposed to OEM delivery delays and engine/avionics component constraints; backlog alone is not a cash-flow substitute. A sustained deleveraging trajectory is likely more important to valuation than a prospective dividend or buyback.

The more differentiated second-order beneficiary of fleet modernization may be Airbus (AIR) rather than BA: incremental A320-family deliveries pull through avionics content while avoiding HONA’s execution and financing risk. HONA’s large IndiGo-related content award supports multi-year installed-base economics, but its revenue recognition is paced by Airbus production rates and airline financing/delivery schedules, not contract announcements. BA remains a less clean read-through because certification, production quality, and supplier remediation can overwhelm favorable avionics demand.

A relative-value long HONA/short HON is attractive only after HONA demonstrates two consecutive quarters of stable margin and positive FCF conversion. HON’s automation exposure is more cyclical and capex-sensitive, while HONA should command a higher-quality aftermarket/defense valuation if leverage falls; however, the spread is vulnerable if industrial automation orders recover or aerospace supply bottlenecks worsen. SOLS has only indirect aerospace exposure and should not be treated as a fleet-cycle proxy; fluorochemical regulatory and customer-concentration risks can dominate aviation-related demand.

Key Decisions for Investors

• Watch HONA’s next earnings for FCF conversion, net-debt/EBITDA, and reaffirmed organic-growth guidance; initiate a long only if management evidences a credible path to leverage reduction and does not lower delivery assumptions again. Thesis fails on another guidance cut or deteriorating aftermarket margins.
• Consider a 6-12 month pair trade: long HONA / short HON in equal beta-adjusted dollars after HONA reports stable standalone execution. Target a 15-20% relative return from aerospace multiple expansion; stop if HON’s automation orders turn positive while HONA’s margin or cash conversion misses.
• Use AIR as the lower-risk aerospace-cycle expression over BA for the next 12 months, particularly if narrowbody delivery cadence improves. AIR captures higher production volume without HONA’s balance-sheet risk; reduce if airline deferrals rise or Airbus delivery guidance is cut.
• Avoid allocating to SOLS solely on aerospace optimism; maintain it as a regulatory watch item pending disclosure of fluorochemical volume, pricing, and any PFAS-related liability or capex requirements.